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Tyrosine hydroxylase (TH; tyrosine 3-monooxygenase) is an enzyme that catalyzes the first 
and rate-limiting step in the biosynthesis of neurotransmitters and hormones dopamine (DA), 
noradrenaline and adrenaline. The iron-containing enzyme uses (6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin (BH4) as cofactor and molecular oxygen (O2) to hydroxylate the substrate 
L-tyrosine (L-Tyr) to L-3,4-dihydroxyphenylalanine (L-DOPA), which is the precursor of DA. 
Tyrosine hydroxylase deficiency (THD), also known as Segawa syndrome, is caused by a 
mutation in the TH-gene resulting in misfolding of TH. A novel approach to treat misfolding 
diseases is the use of small molecules called pharmacological chaperones that correct the 
folding of mutant proteins, thus recovering the protein activity.  
 
The search for pharmacological chaperones that stabilize TH and its disease-associated mutant, 
involved experimental screening of compound libraries containing a total of 1624 compounds 
(Prestwick) using differential scanning fluorimetry (DSF), followed by concentration-
dependent binding assay and activity assay with hit compounds as validation of stabilizing 
efficacy and functionality on TH. The hit compounds were further tested using limited 
proteolysis and isothermal titration calorimetry (ITC) for further characterization regarding 
binding and conformational changes of TH. Finally, a docking program was used to analyze 
possible binding pockets on TH with the hit compounds.  
 
By combining experimental and virtual methods in this work, we identified four primary hit 
compounds and one compound shows potential as a pharmacological chaperone. The THD-
associated mutant bind to the hit compounds to a lesser extent than wild-type TH as it appears 
that this common mutation cause a discrete conformational change of the tetrameric structure. 
The identified compounds might have a potential in pharmacological chaperone therapy for 






CD  Catalytic domain 
CNS  Central nervous system  
DA  Dopamine 
DMSO Dimethyl sulfoxide 
DSF  Differential scanning fluorimetry  
HPLC  High performance liquid chromatography 
IPTG   Isopropyl--D-1-thiogalactopyranoside 
ITC   Isothermal Titration Calorimetry  
kDa  Kilodaltons  
Km  The Michaelis constant   
L-DOPA L-3,4-dihydroxyphenylalanine  
MBP   Maltose binding protein 
OD  Optical density or oligomerization domain 
OMIM  Online Mendelian Inheritance in Man  
RD  Regulatory domain 
SDS-PAGE Sodium dodecyl polyacrylamide gel electrophoresis  
SEC  Size-exclusion chromatography 
SO  SYPRO Orange  
TH        Tyrosine hydroxylase  
Tm  Midpoint temperature 
Wt  wild-type  




1.1 Tyrosine hydroxylase 
Tyrosine hydroxylase (TH; tyrosine 3-monooxygenase) is an enzyme that catalyzes the first 
and rate-limiting step in the biosynthesis of the catecholamine neurotransmitters and hormones 
dopamine (DA), adrenaline and noradrenaline (Molinoff et al., 1971). In the central nervous 
system (CNS), TH is found in the brain and is otherwise localized in the sympathetic nervous 
system, gut, retina and the adrenal medulla (Nagatsu et al., 1964). DA serves both as a 
neurotransmitter released by nerve cells to send signal to other neurons and as a hormone 
outside the CNS, its most important function however is in the brain (Axelrod et al., 1972; 
Molinoff & Axelrod, 1971). Adrenaline and noradrenaline mainly function as hormones 
produced by the adrenal medulla and certain neurons primarily to stimulate the fight-or-flight 
response. TH, an iron-containing monooxygenase, uses (6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin (BH4) as cofactor and molecular oxygen (O2) to hydroxylate the substrate 
L-tyrosine (L-Tyr) to L-3,4-dihydroxyphenylalanine (L-DOPA). BH4 is often referred to as a 
cofactor, when in fact is a co-substrate that is also hydroxylated in the reaction and dissociates 
from the active site in each cycle (Fitzpatrick, 1999; Nagatsu et al., 2018). L-DOPA is the 
precursor for DA, and adrenaline and noradrenaline are in turn synthesized from DA. An 
overview of the catecholamine synthesis pathway is shown in Figure 1.1.  
TH belongs to the family of aromatic amino acid hydroxylases (AAAHs) which also includes 
phenylalanine 4-hydroxylase (PAH) and the tryptophan 5-hydroxylases (TPH1 and TPH2). The 
AAAHs have evolved from a common ancestral PAH (Siltberg-Liberles et al., 2008) and are 
structurally and functionally similar. They catalyze the rate-limiting step of their respective 
metabolic pathways through hydroxylation of their aromatic amino acid substrates. PAH is 
located mainly in the liver and catalyzes the hydroxylation of L-phenylalanine (L-Phe) to 
L-Tyr, the first step in the degradation pathway of L-Phe, while TPH1 and 2, which are present 
mainly in the brain, catalyze the hydroxylation of L-tryptophan to 5-hydroxytryptophan, the 
first step in the biosynthesis of serotonin and melatonin (Roberts et al., 2013). 
Humans have four isoforms of TH (hTH1-hTH4), which differ only in the length of their 
N-terminal regulatory domain (RD). The differences originate from pre-mRNA splicing, 
resulting in insertion of additional amino acids after methionine in position 30 (Daubner et al., 
2011). In this thesis, we are working with TH1, the isoform that is most abundant in the brain 
(Lewis et al., 1993) and the shortest among the four TH isoforms, presenting  no insertions 
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(Kaneda et al., 1987). Also, TH1 is the isoform that corresponds to only TH enzyme in rats and 
most other mammals and is often used in in vitro investigations and studies (Haycock, 2002). 
Thus, TH1 will in this thesis be referred to as TH.  
 
Figure 1.1: The catecholamine synthesis pathway. The pathway is initiated by hydroxylation of L-Tyr to L-DOPA 
by TH, which is the rate-limiting step. This reaction is dependent on BH4 and thus on the required regeneration of 
this co-substrate.  
 
1.1.1 Structure of tyrosine hydroxylase  
TH is a complex tetrameric enzyme where each of the four identical subunits is composed of 
three domains with hinges that facilitate movements and flexibility. Each subunit consists of an 
N-terminal RD with an extended N-terminus with regulatory phosphorylation sites, a central 
catalytic domain (CD) containing the active site iron and a C-terminal oligomerization domain 
(OD) that facilitates dimerization and subsequent tetramerization (Figure 1.2) (reviewed in 
(Daubner et al., 2011)). The exact domain borders in TH are not defined, but the approximate 
transitions are at residues 160 (RD to CD) and 456 (CD to OD) (Figure 1.2A). To date, 
crystal structure determination of the 3D structure of full-length TH has not been successful, 
although the crystal structure of truncated forms containing only the CD and OD were published 
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more than 20 years ago (Figure 1.2B) (Goodwill et al., 1997; Goodwill et al., 1998). More 
recently, the structure of the isolated RD has been visualized by NMR (Figure 1.2C) (Zhang et 
al., 2014) and two low-resolution small-angle X-ray scattering (SAXS) structures of full-length 
TH have recently been published, although suggesting a somewhat contradictory shape of TH 
(Figure 1.2D) (Bezem et al., 2016; Szigetvari et al., 2019).   
1.1.1.1 The regulatory domain  
It is known that the AAAH enzymes have very similar structures. One exception is the RD in 
TH which is substantially longer than in PAH and TPH1. The 70 amino acids long N-terminal 
tail in TH has four phosphorylation sites (Ser/Thr-8, Ser-19, Ser-31 and Ser-40) that are 
important for regulation of TH-activity (Campbell et al., 1986).   
The solution structure of the isolated RD of rat TH has been solved using NMR spectroscopy 
establishing that the RD (residues 65-159) is an ACT domain (Zhang et al., 2014) (Figure 1.2C). 
Two RD monomers are joined to form an ACT domain dimer and if this applies to the RDs in 
the full-length TH as suggested by Bezem et al., the dimer is creating a tetramer both via the 
RDs and the OD (Bezem et al., 2016). This is however still a debated issue (Szigetvari et al., 
2019). An ACT domain is characterized by a ferredoxin-like -fold which consists of 
an antiparallel sheet of eight strands and four -helices located on one side of the sheet 
(Chipman et al., 2001). ACT domains (named after the first letters of aspartate kinase, 
chorismate mutase and tyrA) are involved in the binding of regulatory ligands (small molecules) 
and are also found in other metabolic enzymes, e.g. phosphoglycerate dehydrogenase, aspartate 
kinase and PAH (Grant, 2006).   
1.1.1.2 The catalytic domain  
The CD is in the region from residues 160-456 (Daubner et al., 2011; Goodwill et al., 1997). 
This region is made up of approximately 50% -helices, 10% -sheet and 40% random coil 
(Tekin et al., 2014). This domain contains the active site that lies in a 17 Å deep cleft at the 
centre and is lined primarily by four -helices (6-9) (Goodwill et al., 1997). There are two 
loops (residues 423-428 and 290-296) guarding the opening into the active site. Within the 
active site cleft, there are three coordinating residues required for iron binding: His 331, His 
336 and Glu 376. They are ligands to the iron atom that must be in the ferrous state (Fe2+) to 
carry out the catalysis. The iron atom is 10 Å below the enzyme surface. This arrangement of 
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metal binding formed by His 331, His 336 and Glu 376 residues is referred to as the 2-his-
carboxylate facial triad (Daubner et al., 2011). 
The iron atom in the active site is essential for the role that the catecholamines play in regulation 
of TH-activity. All the catecholamines bind to TH via the iron atom when it is in its ferric form 
(Gordon et al., 2008; Tekin et al., 2014). DA has also shown to competitively bind in the 
cofactor binding pocket. There are crystal structures of PAH CD bound to catecholamines, BH4 
and a substrate analog (Andersen et al., 2002; Erlandsen et al., 1998). Although there is no 
crystal structure of TH with catecholamines bound, it is likely that the binding arrangement of 
DA in the active site of TH is similar (Daubner et al., 2011). 
1.1.1.3 The oligomerization domain  
The OD consists of two main elements; a dimerization motif composed of two -strands (7 
and 8) and a tetramerization -helix (Goodwill et al., 1997). For each subunit the OD begins 
with the dimerization motif which is then followed by the 14-helix. There are twenty-four 
amino acids forming the 14-helix in the OD, which forms an anti-parallel coiled coil cylinder 
located in the middle of the four subunits, connecting the dimers to a tetramer. In the SAXS 
model of TH where the RDs are separate, these helices are the only interaction points between 
the dimers (Szigetvari et al., 2019). This is the arrangement seen in rat PAH (Arturo et al., 2016; 
Meisburger et al., 2016). The -helices interact with each other through hydrophobic residues. 
The contact between the hydrophobic leucine (Leu) residues mediate a 3D-structural motif 
called a leucine zipper, which makes the interaction between the -helices especially stable 
(O'Shea et al., 1989). This enables two dimers to interact with each other, making TH a dimer 





Figure 1.2: The published structures of TH. (A) shows the domain boundaries in different colors, corresponding to 
(B) the CD and OD (crystal structure lacking the RD, PDB ID: 1TOH), (C) the RD (NMR structure, PDB ID: 2MDA). In 
(D) the low-resolution solution structure of full-length TH is shown (Bezem et al., 2016).  
 
1.1.2 The catalytic mechanism 
The cofactor BH4, O2 and iron are required for TH to carry out the hydroxylation of L-Tyr to 
form L-DOPA. Studies suggest that BH4 must bind before the amino acid substrate so that an 
opening site for oxygen occurs in the presence of both substrate and cofactor (Roberts & 
Fitzpatrick, 2013). The binding pocket for BH4 is made up of Glu332, Phe300, Tyr371 and 
Ser368 and Arg316, Ser395, Pro327 and Trp371 form the binding site for the substrate (Teigen 
et al., 2007). During the hydroxylation reaction, BH4 serves as an electron donor producing 
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water by giving two hydrogens to one atom from molecular oxygen (Fitzpatrick, 1999; Nagatsu 
et al., 2018). The mechanism of oxygen activation is not fully understood but it is thought that 
the activation of the enzyme is initiated when oxygen reacts with ferric iron (Fe3+) forming an 
Fe3+- superoxide intermediate that further reacts with BH4 to form an Fe2+-peroxypterin species. 
This Fe2+-peroxypterin intermediate is the precursor of the reactive Fe(IV)=O intermediate 
which is believed to hydroxylate the amino acid (reviewed in (Roberts & Fitzpatrick, 2013)). It 
has been shown that ferrous iron is required and that no other metal is catalytically active. In 
fact, divalent metals such as Ni2+, Zn2+ and Co2+ appear to inhibit TH activity (Bezem et al., 
2016; Haavik et al., 1991).  
1.1.3 Regulation of tyrosine hydroxylase activity 
Catecholamines are important neurotransmitters in the CNS and hormones in the endocrine 
system. Owing to their physiological and behavioral role in movement, cognition, emotion, 
pain, memory processing and endocrine modulation the TH activity is strictly regulated 
(Kobayashi, 2001; Tekin et al., 2014). Catecholamines must be synthesized in appropriate 
amounts depending on the situation as an excess is neurotoxic; the monoamines undergo 
oxidation reactions generating toxic catechol quinones, which can be accelerated by high 
amounts of metal ions such as iron, that lead to cellular macromolecular damage and eventually 
cell death (Hastings et al., 1994; Stokes et al., 1999). A strict regulation of TH activity is 
therefore important as it minimizes the toxic quinone formation and maintains the optimal level 
of catecholamines. TH activity is mainly controlled by three mechanisms; feedback inhibition 
by catecholamines (negative feedback), phosphorylation and dephosphorylation of serine 
residues, and by the concentration of cofactor and substrate (L-Tyr) (Nagatsu et al., 2018; Tekin 
et al., 2014). These regulatory mechanisms are short-term regulations and will be introduced in 
the following sections. 
1.1.3.1 Feedback inhibition by catecholamines  
Feedback inhibition by catecholamines, combined with phosphorylation, is one of the main 
short-term regulation mechanisms for TH activity. This negative feedback can be divided in 
two parts (Tekin et al., 2014). The first is when DA competes with BH4 for active-site binding 
as both molecules have overlapping binding sites (Kumer et al., 1996). This makes DA a 
competitive inhibitor of TH. DA also inhibits TH in a non-competitive manner towards L-Tyr. 
The second inhibition mechanism is when DA binds directly to the active site, via the ferric 
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iron (Fe3+) atom, generating a tight enzyme-iron-catecholamine complex which prevents further 
activation of the enzyme (Andersson et al., 1988). The conformation of the RD is altered when 
DA binds to TH, prohibiting entry of substrates into the active site (reviewed in (Daubner et 
al., 2011)). It is suggested that the effect of DA binding also converts TH to its stable resting 
state (Fujisawa et al., 2005).  
1.1.3.2 Activation by phosphorylation  
The second short-term regulation of TH activity is reversible phosphorylation of threonine 
(Thr) or serine (Ser) residues in position 8, 19, 31 and 40 in the RD (Campbell et al., 1986; 
Daubner et al., 2011; Ramsey et al., 1998). Tekin et al. have reviewed a range of protein kinases 
that are involved in the phosphorylation reaction, showing that each phosphorylation site has a 
main kinase responsible for their phosphorylation (Tekin et al., 2014). Ser19 is phosphorylated 
by calcium-calmodulin-dependent protein kinase II (CaMPKII), Ser31 by extracellular signal-
regulated kinase 1 and 2 (ERK1/2) and Ser40 by cAMP-dependent protein kinase A (PKA) 
(Haycock, 1993; Ramsey & Fitzpatrick, 1998). However, there is lack of evidence that 
phosphorylation of Ser/Thr8 has any regulatory effect on TH activity (Dunkley et al., 2004). 
Moreover, phosphorylation of Ser19 does not increase the TH activity directly but does in fact 
increase the phosphorylation rate of Ser40 (Gordon et al., 2008) and induces the interaction 
with the stabilizing 14-3-3 proteins, which is a family of conserved regulatory molecules 
(Kleppe et al., 2001). Data has been reported that phosphorylation of Ser19 can potentiate 
phosphorylation of Ser40 in intact cells (Bobrovskaya et al., 2004). Phosphorylation of Ser40 
will decrease the affinity for DA 300-fold and relieve it from catecholamine inhibition, thus 
increasing the enzyme activity (Daubner et al., 2011). The phosphorylation of Ser31, that causes 
a decrease in the Michaelis constant (Km) for BH4, will also increase enzyme activity but to a 
much lesser extent (Dunkley et al., 2004). Recently, phosphorylation of TH at Ser31 has been 
associated with the interaction of the enzyme with the vesicular monoamine transporter 
(VMAT2), targeting TH for transport to the terminals (Jorge-Finnigan et al., 2017).  
1.1.3.3 Negative cooperativity of BH4 binding and substrate inhibition  
There has been reported a potential third regulation mechanism of TH activity in vitro where 
BH4 shows negative cooperative behavior towards TH (Flatmark et al., 1999). The underlying 
principle of negative cooperativity is that when BH4 binds to the active site of TH, a 
conformational change occurs which results in decreased ligand affinity, both in equilibrium 
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binding and in kinetic studies (Flatmark et al., 1999). Thus, the ligand affinity decreases with 
increasing amount of bound ligand. Therefore, TH activity also depends on the concentration 
of BH4. At last, the enzyme activity is also dependent on the concentration of L-Tyr. At very 
high levels of the L-Tyr (>50 M), TH is subjected to very strong inhibition (Quinsey et al., 
1998). Indeed, substrate inhibition plays a role in TH-regulation and hence in the biosynthesis 
of catecholamines.  
 
1.1.4 Dysfunctions of tyrosine hydroxylase and disease  
Catecholamines are produced in the brainstem, nerve tissue and adrenal glands and play roles 
in many brain functions such as memory, cognition, movements, emotion and attention 
(reviewed in (Daubner et al., 2011)). The importance of DA is evident in the neurodegenerative 
Parkinson’s disease (PD) which is characterized by selective and severe loss of dopaminergic 
neurons in substantia nigra causing lack of DA in these brain areas (Haavik et al., 1998; Zhu et 
al., 2012). Since adrenaline and noradrenaline are involved in maintaining blood pressure and 
blood sugar, dysfunction and subsequent reduction in DA synthesis will affect these 
cardiovascular and endocrine systems as well.  
Most often dysfunction of TH is caused by mutations in the TH-gene which affect the folding 
of TH and lead to a disease called tyrosine hydroxylase deficiency (THD), also known as 
Segawa syndrome (OMIM #605407). THD is an autosomal recessive disorder manifesting as a 
progressive movement retardation and include clinical features such as tremor, rigidity, chorea, 
bradykinesia, hypokinesia and dystonia. The diagnosis is based on clinical symptoms and 
measurements of normal concentration of 5-hydroxyindolacetic acid (5-HIAA), low 
homovanillic acid (HVA), low 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and low 
HVA:5-HIAA ratio in cerebrospinal fluid. The homovanillic acid is the catabolic product of 
DA in CNS whereas MHPG is from noradrenaline. 
As is the case in PD, most THD patients are mainly treated with L-DOPA – the precursor of 
DA – which is used therapeutically because of its ability to cross the blood-brain barrier (BBB) 
by an amino acid transporter called system L (Kageyama et al., 2000). In the brain, 
dopaminergic neurons will convert L-DOPA into DA, catalyzed by aromatic amino acid 
decarboxylase, increasing the dopamine level. L-DOPA is usually co-administrated with a 
decarboxylase inhibitor to block the conversion of L-DOPA to DA within peripheral tissues, 
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thus preventing possible adverse side effects and also for avoiding loss of L-DOPA in the 
circulation (Bartholini et al., 1967; Willemsen et al., 2010). The decarboxylase inhibitors, e.g. 
carbidopa, selectively inhibit peripheral but not the neuronal decarboxylase, as the 
decarboxylase inhibitors are unable to cross the BBB (Hoffmann et al., 2003). L-DOPA is 
therefore known as a dopamine replacement agent that is also used in treatment of THD. 
Patients diagnosed with THD are categorized into two subgroups: type A is a mild progressive 
neurological condition with onset in infancy that is responsive to L-DOPA treatment, and type 
B is a more severe complex encephalopathy with neonatal onset that is L-DOPA-nonresponsive 
(reviewed in (Willemsen et al., 2010)). However, long-term L-DOPA treatment is associated 
with side effects, for type B patients especially, and is not considered as being sufficient for 
efficient treatment (Pons et al., 2013). Thus, an alternative therapeutic treatment is highly 
needed for these severe THD patients. 
1.1.4.1 Mutant R202H-hTH1 
The most common missense mutation in THD is Arg233His (TH-p.R233H) in exon 6 in isoform 
4 of human TH (hTH4) (Fossbakk et al., 2014; Hoffmann et al., 2003). TH-p.R233H is caused 
by a mutation of the arginine (R) in position 233 to a histidine (H) resulting in decreased enzyme 
stability and activity. The R233 is equivalent to R202 in hTH1. From now on, this mutation 
will therefore be referred to as R202H.  
The R202H mutation accounts for about 30% of all alleles in the THD cases studied (Willemsen 
et al., 2010). The mutant is associated with autosomal recessive L-DOPA-responsive infantile 
parkinsonism (Hoffmann et al., 2003) and also both type A or type B THD, although there is 
an abundance of type B patients when in homozygosity (Willemsen et al., 2010). Patients 
diagnosed with L-DOPA-responsive dystonia caused by the R202H mutation have been 
reported in The Netherlands (van den Heuvel et al., 1998).  
There are several studies that have been conducted to investigate different therapeutic strategies 
and increase our understanding on the R202H mutant (Calvo et al., 2010; Hole et al., 2016; 
Korner et al., 2015). Korner et al. discovered that mice with the R202H mutation (R203H in 
mice) lacks TH in the brain striatum, which has also been shown to be associated with PD. TH 
is expressed in the substantia nigra and the lack of TH in the striatum was explained by Korner 
et al. to be caused by the inability of the mutant TH to bind and be stabilized by DA. As it is 
believed that TH is transported in the dopaminergic pathway from the substantia nigra to the 
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striatum as a TH-DA complex, a functional transport of the TH-R202H will not be possible, 
since DA does not bind and stabilize this mutant properly (Korner et al., 2015). R202 is 
positioned in an -helix that lies close to the active site and its ability to form strong bonds to 
E223 and E228 is likely important for keeping the structure of the CD in the correct shape and 
possibly also for keeping DA stably bound (Figure 1.3). In this respect, developing strategies 
to stabilize TH-R202H and other TH mutants will be a potential target for THD, and also other 
genetic dopaminergic deficiencies. 
 
Figure 1.3: Position of R202 in TH. (A) The tetrameric SAXS structure of TH showing the position of R202 (red) in 
each subunit. In the close-up in (B), the - helix where R202 is located is shown in blue and the FE from PDB ID: 
1TOH is placed to show its proximity to the active site. (C,D) the  interaction between the positively charged R202 






1.2 Protein stability  
Protein folding is the physicochemical process by which a polypeptide chain spontaneously 
folds into its native characteristic three-dimensional (3D) structure. The amino acid sequence 
determines the 3D structure of proteins that must be correct for the protein to perform its 
biological function (Dobson, 2003). The transition from the unfolded to the native state involves 
the search for the conformation of correct free energy (G) (Figure 1.4). Failure to fold into the 
native confirmation causes an incorrect protein structure, normally associated with defective 
protein function and stability.  
Inside cells, large protein complexes called molecular chaperones prevent unfolded proteins to 
be tangled up with one another and form unwanted aggregates (Ellis, 1990). These protein 
complexes are part of the cellular protein quality control system that controls the protein 
production status, localization, folding and degradation, which is necessary to avoid misfolding 
and aggregation of proteins (Figure 1.4). Some of these chaperones have also been proved to 
rescue an already misfolded or partially folded protein, enabling them to fold correctly (Dobson, 
2003; Hartl et al., 2011) . A certain level of misfolded non-functional forms of proteins can still 
occur which will lead to gradually build up in cells. The ubiquitin-proteasome system (UPS) 
prevents accumulation of misfolded, damaged and mutant proteins by cellular proteolysis. The 
misfolded proteins are first tagged by a protein known as ubiquitin and then recognized, 
protolyzed and eliminated by proteasomes (Nandi et al., 2006). This is contrary to autophagy, 
a nonselective degradation system, that disassembles dysfunctional or unnecessary components 
without the requirement of specific tag recognition (Mizushima, 2007). The UPS and the 
autophagy lysosomal systems are the two main protein degradation systems in the cell 
(reviewed in (Lilienbaum, 2013)). However, excess of misfolded protein molecules can 
overload the capacity of the UPS and the autophagy systems, allowing soluble aggregates to 
undergo further assembly into amyloid fibrils or plaques which can harm and injure cells 
(Gregersen et al., 2006; Hartl et al., 2002). Deposition of such protein aggregates and amyloid 
fibrils are reported in neurological disorders such as Alzheimer and Parkinson’s diseases 




Figure 1.4: Schematic energy funnel illustrating the folding process of proteins. Unfolded conformers are seeking 
the correctly folded conformation via intermediate states. Protein complexes, known as molecular chaperons in 
cells, help partially folded proteins to fold to into a native state. (Figure taken from (Hartl et al., 2011)).  
 
 
1.2.1 Pharmacological chaperones  
A wide range of illnesses often occur because of protein misfolding that causes premature 
degradation and/or loss of protein function. However, the protein activity can be recovered by 
small molecules that bind, stabilize and accelerate folding of the native conformation. Such low 
molecular weight molecules are called pharmacological chaperones (PC) as they have similar 
roles as protein chaperones in cells. Instead of assisting in folding, they mainly stabilize an 
already folded but unstable protein by protecting it from proteolytic degradation and aggregate 
formation (Ringe et al., 2009). PCs with high affinity binding to a specific protein is an 
important property for achieving stabilization through molecular interactions including van der 
Waals, electrostatic – and hydrogen binding with residues in the binding site, holding parts of 
the protein structure together thus contributing to a correct protein function (Figure 1.5)  (Hole 
et al., 2016).  
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PCs have the potential to be used as a therapeutic strategy for correction of misfolded mutant 
proteins and have already been implemented in treatment of some protein-misfolding diseases, 
in particular lysosomal storage disorders such as Fabry – and Gaucher disease (Markham, 
2016). The concept of PC therapy is relatively new but has been growing in the research field 
the last years.  
 
 




1.3 From gene to pharmacological chaperone – a methodological overview 
The work presented in this thesis presents the workflow from expression of TH protein to the 
identification of potential PCs using the following methods: 
1.3.1 Recombinant protein expression and purification 
Overexpression of recombinant protein is a known and widely used methodological approach 
in science for making specific proteins that can be used in studies of their function, in drug 
discovery or as biotherapeutics to treat diseases. Recombinant proteins are expressed by using 
various expression systems or hosts including yeast, bacteria, insect- and mammalian cells or 
without the use of living cells. The best protein production system is dependent on the protein, 
e.g. membrane proteins often fail in bacterial systems. However, the most used and well-
established expression system is the bacteria, E.coli in particular, where the cDNA of the gene 
of interest is introduced on a plasmid expression vector (Rosano et al., 2014). Overexpression 
in E.coli is carried out by cloning the cDNA for the protein of interest into a high-copy plasmid, 
often containing the lac or T7 promoter which is induced by lactose or its analog. 
After overexpression, the recombinant proteins in E.coli are purified using an appropriate 
method and used for further studies. The main benefits of bacterial expression are the fast 
exponential growth of the organism and the ease of genetic manipulation. Besides, it only 
requires simple and relatively cheap equipment and materials.  
1.3.1.1 Affinity chromatography 
Affinity chromatography is a method used for separating specific molecules from a complex 
mixture as a step in the purification process of proteins (Urh et al., 2009). Separation is achieved 
by loading the mobile phase, which contains a variety of biomolecules, onto a column 
containing a specific ligand – the stationary phase – that can interact with the biomolecule of 
interest (Figure 1.6A). In order to facilitate the purification of proteins by affinity 
chromatography, different affinity fusion tags are often utilized. Some commonly used affinity 
tags for purification of recombinant proteins are the hexahistidine tag (6xHis-tag), glutathione 
S-transferase (GST), calmodulin-binding peptide (CBP) and maltose-binding protein (MBP) 
(Zhao et al., 2013). 
Target proteins that are fused to the maltose binding protein (MBP) specifically – a widely used 
protein expression tag – permits its purification using amylose resin as the stationary phase 
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(Terpe, 2003). During the chromatography, the target protein binds to the immobilized ligand 
(amylose resin) via the highly specific interactions between the MBP-partner and the resin. All 
other (non-target) biomolecules will be removed by a washing buffer due to their weaker 
interactions with the stationary phase and eventually only the fusion protein will remain on the 
column. When changing the composition of the mobile phase by adding maltose, it will 
outcompete the resin for binding to MBP as its affinity is higher, effectively releasing the fusion 
protein.  
1.3.1.2 Size-Exclusion Chromatography 
Size-exclusion chromatography (SEC), also known as gel filtration, is a chromatographic 
method which separates proteins in solution according to their size as they are filtrated through 
a column containing a porous matrix of specific size distribution (Figure 1.6B). Molecules 
larger than the pores elute first as they are unable to diffuse into the porous matrix, while smaller 
molecules that are able to enter the pores will spend more time in the packed matrix and flow 
through the column more slowly, thus eluting later. Analytical SEC is often used to test the 
quality of a protein sample. This technique will reveal if it contains e.g. aggregates or other 
oligomers and is therefore an important step in monitoring the purification process of proteins. 
Chromatographic conditions such as column length, pore size, flow rate, and volume load are 
important factors that can have a big impact on the resolution, sensitivity and analysis time 




Figure 1.6: Principle of (A) affinity chromatography and (B) size-exclusion chromatography. Figure modified from 
MBL Life Science home page.  
 
1.3.2 Differential Scanning Fluorimetry 
Differential scanning fluorimetry (DSF) is a high throughput method used to determine 
conditions that affect protein stability (Brennecke et al., 2019; Niesen et al., 2007). The method 
relies on the fact that proteins denature when subjected to sufficient heat and when the 
temperature reaches the midpoint temperature (Tm) of the particular protein – defined as the 
temperature where 50% of protein is unfolded - it exposes its internal hydrophobic protein core. 
SYPRO Orange (SO) can be used as a probe as is fluoresces upon binding to hydrophobic 
patches. In DSF the temperature is steadily increased, and the fluorescence intensity is plotted 
as a function of temperature to show the fraction of unfolded protein (Figure 1.7). By comparing 
the Tm-values obtained in different conditions one can identify those that have an impact on 
protein stability. DSF is typically performed by using a real-time PCR instrument such as 
LightCycler that allows high-throughput performance. DSF is an inexpensive method that 
allows rapid analysis of multiple samples simultaneously, thus being an important tool in 





Figure 1.7: The principle of DSF. The fluorescence intensity is plotted as a function of temperature to show the 
fraction of unfolded protein and the midpoint of the curve defines the Tm. Figure taken from Brennecke et al.  
 
1.3.3 TH activity assay 
An assay of TH activity is based on quantification of L-DOPA by high-performance liquid 
chromatography (HPLC) (Haavik et al., 1980). As mentioned previously, TH catalyzes the 
hydroxylation of L-Tyr to L-DOPA in the biosynthesis of catecholamines neurotransmitters 
with an absolute requirement of BH4. Addition of the cofactor is therefore crucial to start the 
catalytic reaction. HPLC with fluorescence detection enables separation of L-Tyr and L-DOPA 
in the solution and since the enzyme activity is directly correlated to the L-DOPA production 
from L-Tyr, L-DOPA is quantified. The chromatographic separation is based on different 
degrees of interaction between the components of the sample and the adsorbent material in the 
column. The separation occurs under significantly higher pressure forcing the molecules to flow 
through very fast. In normal-phase chromatography, the stationary phase is polar while the 
solvent is non-polar. Non-polar molecules in the sample mixture will move with the solvent 
and elute first relative to the polar molecules (such as L-DOPA). The fluorescence emission 
spectra of both components will be detected revealing the L-DOPA production. L-Tyr is excited 
at wavelength 274 nm and emits at 304 nm, while L-DOPA is excited and fluorescence at 281 
nm and 314 nm, respectively (Haavik & Flatmark, 1980). Finally, molecules that bind and 
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stabilize TH can have an impact on the enzyme activity and these are thus added to the enzyme 
solution before starting the assay. 
 
1.3.3.1 EC50 and IC50 
The concepts of EC50 and IC50 are well known in pharmacology and are terms widely used to 
measure the efficacy of a drug. The definition of is EC50 is the concentration of a drug, toxicant 
or compound which induces a response halfway between the baseline and maximum after a 
specified exposure time. The half maximal inhibitory concentration (IC50) however, is the 
concentration of a compound that is required to inhibit a given maximal biological function by 
half (Sebaugh, 2011). The IC50 terminology is used when the maximal effect of a response is 
related to inhibition. This concept is important in drug discovery and was applied in our search 
for pharmacological chaperones for TH. Measurements of EC50/IC50 for compounds allow 
those with pharmacological chaperone potential and those with inhibitory potential to be 
discovered and recognized. In this work, the EC50 and IC50 values were determined using the 
four-parameter logistic nonlinear regression equation in SigmaPlot: 








1.3.4 Limited proteolysis by trypsin  
Limited proteolysis is a simple biochemical method based on a short exposure of a protein to 
low concentration of a proteolytic enzyme (e.g. trypsin). Trypsin is an enzyme that cleaves 
other proteins in flexible areas. For TH, treatment with trypsin has been reported to cleave the 
N-terminal region (70-80 residues), shortening the 60 kDa (full-length) to 57 kDa and 52-54 
kDa (Hole et al., 2015). By N-terminal sequencing of the products, four cleavage sites have 
been identified after arginines in position 33, 37, 38 and 49 making the N-terminal the most 
sensitive region upon proteolysis (McCulloch et al., 1999). It has however been demonstrated 
that the binding of DA decreases the rate of trypsinization, protecting the protein from further 
cleavage (Hole et al., 2015; McCulloch & Fitzpatrick, 1999). The susceptibility of TH to limited 
tryptic proteolysis can thus be tested with different compounds which can support information 




1.3.5 Isothermal Titration Calorimetry  
Isothermal titration calorimetry (ITC) is a technique used to directly measure the heat that is 
absorbed or released during a binding event. This method provides important thermodynamic 
information such as enthalpy (H), entropy (S), reaction stoichiometry (N) and binding 
affinity (Kd). Moreover, ITC gives insight into understanding of the nature of the molecular 
interaction occurring (Leavitt et al., 2001). The calorimeter consists of a sample cell, that 
contains one of the binding partners (e.g. a protein), and a reference cell that contains only 
water. The two cells are kept at exactly the same temperature. As the other binding-partner (e.g. 
a compound) is gradually injected into the sample cell, a binding occurs releasing (or absorbing) 
heat that will be measured. A heat sensing device will detect the temperature differences 
between the cells and therefore compensate for the small heat changes by returning both cells 
to equal temperature. At one point, the protein will get saturated thus limiting binding of 
compound, and the heat transferring will decrease as followed. The system and example results 




Figure 1.8: Illustration of the Isothermal titration calorimetry (ITC) system. The area under each peak correlates 
to fractional heat of binding (in microcalories). The quantity of heat measured, and the amount of binding is 
directly proportional to each other. As the protein is saturated, the peaks have lower intensity. The data is 






1.3.6 Molecular docking  
Molecular docking, also known as target-based virtual screening, is frequently used in drug 
design and analysis. It is a computational method that involves positioning the ligands of 
interest in the binding site of a target protein of known three-dimensional structure generating 
a protein-ligand complex (Meng et al., 2011). The stability of a protein-ligand complex is 
related to its binding free energy, so that the ligand molecule is placed at what is considered to 
be the most energetically favorable position in the site. The binding affinity of the ligand for 
the protein is determined by a scoring function (e.g. Glide score) pointing to whether these 
orientations are the most optimal (Friesner et al., 2004). Molecular docking is an important 
tool not only used in computational chemistry, but also recently in the field of modern drug 
discovery and development. The main aim of the docking process is to predict the 
predominant binding mode of a ligand with a target protein which might give a deeper 
understanding of the structure-function relationship (Morris et al., 2008). 
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2 Aims of the project 
The main objective of the project is to screen and validate compounds with pharmacological 
chaperone potential that stabilize tyrosine hydroxylase (TH) and its disease associated mutants, 
notably TH1-p.R202H. Compounds that correct the conformation of the mutant are also 
expected to correct its localization and function in the brain. An important objective of the thesis 





3 Materials and Methods  
3.1 Materials  
 
Common chemicals not mentioned in the table are supplied by Sigma Aldrich.  
Chemical Supplier 
Luria Bertani Broth (Lennox)  Sigma Aldrich   
Kanamycin sulfate Sigma Aldrich 
Chloramphenicol Sigma Aldrich 
Isopropyl--D-1-thiogalactopyranoside Apollo Scientific 
Ammonium iron (II) sulfate hexahydrate  Sigma Aldrich  
Benzamidine hydrochloride hydrate  Sigma Aldrich  
Phenylmethanesulfonyl fluoride  Sigma Aldrich  
cOmplete EDTA-free tablets  Roche  
Amylose resin BioLabs  
Tobacco Etch Virus protease  Purified in lab E 
D-(+)-Maltose monohydrate  Sigma Aldrich  
Loading buffer/Laemmli Sample Buffer Bio-Rad  
Dithiothreitol  Sigma Aldrich 
Coomassie G-250 Bio-Rad  
Urea  MERCK  
SYPRO Orange 5000X, Invitrogen S6650 Fisher Scientific  
Bovine serum albumin  Sigma Aldrich 
Catalase  Sigma Aldrich  
L-Tyrosine  Sigma Aldrich  
L-3,4-dihydroxyphenylalanine Sigma Aldrich 
Dopamine hydrochloride  Sigma Aldrich  
Ethanol VWR Chemicals 
Acetic acid >99,8% Sigma Aldrich  
Propanol  VWR Chemicals 
Glycerol (solution) 86-89% (T) Sigma Aldrich  
Peptone Sigma Aldrich 
Yeast extract  Merck 
TPCK treated trypsin Sigma Aldrich 
Trypsin soybean inhibitor  Sigma Aldrich 




3.2 Preparation of pure and stable TH enzymes  
In this work, we will focus on expressing His-MBP-TH and the His-MBP-TH-R202H. Tyrosine 
hydroxylase (TH) is expressed with an N-terminal His-tagged Maltose binding protein (MBP) 
fusion partner in bacterial cultures of BL21-CodonPlus by the gene encoding His-MBP-TH in 
the plasmid vector pET-MBP-1a (Figure 3.1). We will do a first attempt to express His-MBP-
TH from a modified and thus novel version of the previously published pET-MBP-1a/TH 
(Bezem et al., 2016). This new construct has been optimized (by deletion mutagenesis) to not 
contain extra residues (GAM) at the N-terminus after cutting with Tobacco Etch Virus (TEV) 
protease. This new fusion protein will be referred to as optimized His-MBP-TH. The previously 
published pET-MBP-1a/TH vector was also used as template to make the hTH1-
p.R202H mutant (Korner et al., 2015).  
 
 
Figure 3.1: Schematic view of the plasmid vector pET-MBP-1a encoding published (left) and optimized (right) His-
MBP-TH. Extra amino acids compared to the native amino acid sequence are denoted in red for both plasmids.  
  
As BL21 CodonPlus is resistant to chloramphenicol (cam) and the pET-MBP-1a plasmid 
confers kanamycin (kan) resistance, both antibiotics are used during growth and expression 
(Figure 3.1). MBP facilitates affinity purification of His-MBP-TH as the MBP binds to amylose 
resin and stays bound during wash-out of other proteins (Terpe, 2003). The high affinity of 
MBP for maltose enables elution with maltose-supplemented buffer. MBP is also used to reduce 
aggregation of recombinant proteins (Waugh, 2016). A modified TEV protease (van den Berg 
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et al., 2006) is used to release TH from the fusion partner as it recognizes and cuts the sequence 
ENLYFQ/(G/S) encoded by the plasmid (Bezem et al., 2016). 
 
3.2.1 Expression of His-MBP-TH proteins 
Luria-Bertani (LB) medium (50 ml) containing 34 g/ml cam and 50 g/ml kan were inoculated 
with E. coli BL21-CodonPlus and incubated overnight at 28C, before diluted in 1 L LB-
medium with the same concentration of antibiotics. The bacterial cultures were shaken (200 
rpm) at 37C and the growth was monitored with Biowave C08000 Cell Density Meter. At 
OD600nm  0.7, 0.5 mM isopropyl--D-1-thiogalactopyranoside (IPTG) was added to induce 
expression of His-MBP-TH and 100 mg of ammonium iron (II) sulfate hexahydrate (FAS) 
was added simultaneously to saturate the TH active site. The cultures were incubated for 22 
hours at 28C. The cultures were harvested by centrifugation at 4000 x g (4C, 20 min) and 
resuspended in a smaller volume and centrifuged for another 20 minutes at 3000 x g (4C) in 
50 ml Falcon-tubes. As a preparation for sonication the pellets were stored at – 80C for about 
2 hours to make the bacteria more fragile. 
The mutant TH-R202H was also expressed in E.coli BL21-CodonPlus, but grown in Terrific 
Broth medium (4 ml/L glycerol, 20 g/L peptone, 24 g/L yeast extract with 0.017 M KH2PO4 
and 0.072 M K2HPO4) and induced for 24 h at 20C.  
 
3.2.2 Purification of His-MBP-TH by affinity chromatography  
The bacterial pellets were resuspended in 5 ml/g Lysis buffer (20 mM Hepes pH 7, 200 mM 
NaCl, 10 mM Benzamidine hydrochloride hydrate, 1 mM Phenylmethanesulfonyl fluoride 
(PSMF) and 1 tablet of cOmplete EDTA-free/70 ml buffer) and sonicated on ice in three 
rounds of 45 s using a Sonics Vibra cell (pulser 9 sec, output 20 Watts). The sonicate was 
centrifuged for 30 min at 23500 x g (4C), and the crude extract containing soluble proteins 
was collected. For the wild-type proteins, amylose resin (5 ml/L original culture volume) was 
equilibrated with Binding buffer (Lysis buffer without protease inhibitors) and incubated with 
the crude extract for 3 hours in the cold room on a rotary wheel before most of the unbound 
proteins were removed by centrifugation (2844 x g, 10 min at 4C) and the amylose resin was 
transferred to an empty XK-column connected to an ÄKTAprime Plus Liquid Chromatography 
system (GE Healthcare) at 4C. For the mutant fusion protein, the crude extract obtained was 
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loaded into empty PD-10 columns (GE Healthcare) containing buffer-equilibrated amylose 
resin (2.5 ml/original culture volume) in the cold room until all the extract had run through by 
gravity flow and subsequently washed with Binding buffer. In both methods, the resin was 
washed with Binding buffer until the OD280nm was below 0.01. 
The His-MBP-TH proteins were eluted with Elution buffer (Binding buffer with 10 mM 
maltose) using a flow rate of 2 ml/min (for the normal, wild-type (wt) TH) or gravity (for the 
TH-R202H mutant). Eluted fusion protein were concentrated in 15 ml Amicon Ultra-15 50 
MWCO Centrifugal Filter Devices and the protein concentration was measured 
spectrophotometrically at 280 nm using 280 (1 mg/ml) = 1.63. The fusion proteins were stored 
in liquid nitrogen for later use.  
Sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) was used to evaluate the 
purification process and check the purity of the His-MBP-TH proteins. Samples were diluted 
1:1 in 2x loading buffer (LB) with fresh dithiothreitol (DTT) and heated at 95C for 5 min 
before applied to a Mini-PROTEAN TGX Precast Gel (Bio-Rad) in a Bio-Rad Mini-
PROTEAN Tetra Cell system with Tris-glycine-SDS (TGS) running buffer. Low molecular 
weight marker (LMW) (Bio-Rad SDS-PAGE Molecular Weight Standards, Low range) was 
used to determine the size of the proteins. The gel ran at 300 V for 15 minutes. After the 
electrophoresis the gel was immersed in Coomassie Blue G-250, heated in the microwave and 
gently agitated at room temperature until bands appeared. After destaining with water, the gel 
was photographed using a Bio-Rad ChemiDoc XRS+.  
 
3.2.3 Removal of tag and isolation of TH  
3.2.3.1 Testing the quality of fusion protein by SEC  
The quality and oligomeric distribution of the original and optimized wild-type and of the 
R202H mutant fusion proteins were analyzed by size-exclusion chromatography (SEC) at a 
flowrate of 0.5 ml/min. SEC separates proteins in solution by size and thus, the analysis reveals 
if our purified fusion protein samples contain aggregates, the expected tetramer of His-MBP-
TH or other oligomers. The column used was a Superdex 200 Increase 10/300 connected to 




3.2.3.2 Optimizing TEV-protease cutting 
As the amino acid sequence around the TEV-protease cleavage site (ENLYFQ/G) in the 
optimized His-MBP-TH is reduced by 3 amino acids (GAM) as shown in Figure 3.1, the linker 
between the MBP and TH is shorter than in the fusion protein previously published (Bezem 
2016). As this change can potentially influence the access to the TEV protease cutting site and 
thus the efficiency of the cutting, cutting tests with TEV-protease were performed under 
different conditions. The cutting of the His-MBP-TH-R202H-mutant was also tested. 
The first test was performed with the optimized His-MBP-TH. To test different protein:protease 
ratios and incubation-time, 10 µg samples were mixed with either 0.2 µg TEV-protease (1/50 
w/w ratio) or 1 µg TEV-protease (1/10 w/w ratio) and incubated at 4C. Samples from both 
ratios were taken out after 1, 2 and 3 hours. To stop the reaction the samples were immediately 
mixed with loading buffer containing DTT and heated at 95C for 5 minutes before loading 
onto the gel at the end of the experiment. The gel electrophoresis and staining were performed 
as in section 3.2.2. In the second test, the cutting of the optimized His-MBP-TH was compared 
to the cutting of the original His-MBP-TH at the same ratios, and the effect of adding 0.5 M 
urea to the reaction was also tested on both for 1 h. The third test was performed on the His-
MBP-R202H protein using the same conditions as in the first test, but at protease/protein ratios 
of 1/10, 1/50 and 1/100 for 1 h at 4C. 
 
3.2.3.3 Isolation of TH from His-MBP-TH 
To obtain pure TH, His-MBP-TH was mixed with 1/50 TEV-protease (w/w ratio) for 1.5 h at 
4C and separated from the fusion partner and aggregates by SEC as performed in section 
3.2.3.1. Fractions containing tetrameric TH were concentrated in 15 ml Amicon Ultra-15 50 
MWCO Centrifugal Filter Device for 30 min at 4C and the concentration was measured at 280 
nm using 280 (1 mg/ml) = 1. The purity of TH was examined by running SDS-PAGE at the end 
of the experiment. The TH-R202H mutant was isolated from the fusion partner in the same 
way, except that a 1/10 ratio of protease/protein was used. 
 
3.2.4 Finding an appropriate buffer for TH by DSF  
In this work we tested the stability of TH-wt in the commercial RUBIC Buffer Screen MD1-96 
(Molecular Dimensions Ltd), a set of 96 different conditions chosen according to pH, salt 
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concentrations, buffer type and concentrations designed at the EMBL Hamburg (Appendix), 
and a more limited home-made buffer screen with different concentrations of NaCl.  
 
3.2.4.1 RUBIC Buffer Screen 
The RUBIC Buffer Screen MD1-96, reviewed in (Senisterra et al., 2009), was tested according 
to the RUBIC Buffer Screen protocol (Appendix) with 0.075 mg/ml TH-wt and 5x SO. 
Multichannel pipetting of protein and SO into the 96 wells, each containing different buffer 
conditions, was performed by the TTP labtech mosquito High Volume (HV) and the plate 
was sealed using the Axygen PlateMax Semi-Automated Plate Sealers (Axygen Scientific) 
and heated from 20-99 °C using the LightCycler 480 Instrument II plate-based real-time PCR 
System (Roche Life Science) at 4.5°C/min.  
 
3.2.4.2 NaCl concentrations 
To further determine optimal buffer conditions for TH-wt, we prepared a buffer screen with 20 
mM Hepes pH 7 and five different concentrations of NaCl; 100 mM, 200 mM, 300 mM, 400 
mM and 500 mM NaCl. Triplicate samples were prepared and analyzed with 0.075 mg/ml TH-
wt and 5x SO as described but with manual pipetting.  
 
3.3 Finding potential pharmacological chaperones for TH 
The search for compounds that increase TH stability is based on a high-throughput screening 
of different chemical libraries using DSF (Niesen et al., 2007). For TH, screening of the 
MyriaScreen diversity collection with 10 000 compounds (Sigma Aldrich/TimTec) and 
validation of obtained hits has already been performed and published (Hole et al., 2016; Hole 
et al., 2015). In addition, a library of FDA-approved drugs (1280 compounds) 
(http://www.prestwickchemical.com/libraries-screening-lib-pcl.html), here referred to as FDA, 
has been screened, but the hits are not yet validated. In this work we set out to validate these 
hits and in addition we screened a library of Innovative Compounds amenable to modification 
(344 compounds) (http://www.prestwickchemical.com/libraries-screening-lib-pom.html). This 
library, here referred to as NOCE, has been selected for their favorable drug-like and ADME-
Tox pharmacological properties; absorption, distribution, metabolism, excretion and toxicity 
(Di et al., 2009).  
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3.3.1 Screening of the NOCE library by high throughput screeing using DSF  
In order to identify potential high-quality hits from the NOCE library, 0.075 mg/ml of protein 
in 20 mM Hepes pH 7, 200 mM NaCl and 5X SO was pipetted into a 384-well plate using the 
Thermo Scientific Multidrop Combi instrument. The prepared protein solution and 
compounds (dissolved in 100% DMSO) were mixed in each well and DSF was run as 
previously described with wells containing 5% DMSO instead of compound as reference. 
Compounds that stabilized TH  1.8C were considered primary hits and selected for further 
validation. 
 
3.3.2 Validation of primary hits on TH  
The primary hits obtained from the NOCE library and hits previously obtained from the library 
of FDA-approved drugs (Prestwick Ltd) were further validated by concentration-dependent 
binding assays.  
 
3.3.2.1 First validation  
For the first validation, the compounds were diluted by a factor of 2 for each concentration with 
20 mM Hepes pH 7, 200 mM NaCl and 5X SO using the Serial Dilution program on the TTP 
labtech mosquito HV, making a concentration range from 250 M to 0.12 M. TH-wt (final 
concentration of 0.075 mg/ml) was then added to each well using Thermo Scientific 
Multidrop Combi. The unfolding was monitored by DSF as described. Compounds that 
showed a tendency towards binding that was concentration-dependent were selected for further 
validation. 
 
3.3.2.2 Second validation  
Hits obtained after the first concentration-dependent assay were selected for a second validation 
diluted by a factor of 1.33 to make 24 concentrations ranging from 500 M to 0.7 M as 
described. The EC50-values was determined by using equation (1) in SigmaPlot. The primary 
hits were also tested on the mutant with a 24 concentrations range as for TH-wt and the EC50-




3.3.2.3 Testing the stabilizing effect of DA on TH 
TH-wt and TH-R202H (final concentration of 0.075 mg/ml) were tested with increasing 
concentration of DA using DSF. The standard mix contained the TH which was incubated with 
5 M FAS for 2 min at room temperature (RT) before added to solution containing buffer and 
5X SO. DA was added to the standard mix and allowed to bind 5-10 minutes at RT before 
starting DSF.  
 
3.4 Evaluating the effect of hit compounds on TH activity 
 
3.4.1 Testing inhibitory effect on TH 
The effect of hit compounds on the enzymatic activity of TH was determined by a well 
established enzymatic activity assay (Haavik & Flatmark, 1980) at 37C. TH was diluted with 
0.005% bovine serum albumin in 20 mM Hepes pH 7, 200 mM NaCl and added to a final 
concentration of 0.01 mg/ml in 40 mM Hepes pH 7, 0.1 mg/ml catalase, 10 M ferrous 
ammonium sulphate, 50 M L-Tyr and ~100 µM compound. After preincubation at 37C for 1 
min, the reaction was started by adding 200 M BH4 and 5 mM DTT and stopped after 5 min 
with cold 2% (v/v) acetic acid (Hac) in ethanol. After 90 min at -20C, the samples were 
centrifuged at 20000 x g for 14 min at 4C to remove precipitated protein. The reference activity 
assay was performed without compound, but with 2% DMSO. 
The samples were analyzed by high performance liquid chromatography (HPLC) using a polar 
bonded-phase Agilent Zorbax 300-SCX column (4.6 x 150 mm) connected to Agilent 
Technologies 1290 Infinity II LC System at 4C. A pump forced a liquid mobile phase of 1 
mM Hac buffer (pH 3.5) with 0.2% (v/v) propanol through the column at a flowrate of 3 ml/min. 
Standards of L-DOPA at 39.6 M and 20 M was dissolved in 1.25 mM L-Tyr and 2% (v/v) 
Hac in ethanol, respectively. In order to detect L-DOPA the excitation wavelength (ex) of 280 
nm was used with emission wavelength (em) set to 314 nm. L-DOPA was quantified from the 
HPLC chromatogram. The Student`s t-test was performed (section 3.8) to determine whether 
the difference was significant compared to the control without compound (*p-value <0.05).  
For compounds that inhibit TH activity, the half maximal inhibitory concentration (IC50) was 
determined. The determination of IC50 value for the compounds was performed by the described 
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activity assay in the presence of 0-100 M compounds. The DMSO concentration was kept 
constant at 2%. The samples were analyzed using HPLC as described. The fitting and 
determination of IC50 value was obtained using the four-parameter logistic nonlinear regression 
equation in SigmaPlot.  
 
3.5 Protection of TH towards limited proteolysis by trypsin  
Before testing the ability of the hit compounds to confer structural protection against proteolysis 
of the TH protein, we optimized conditions for length and TH:trypsin ratio (50:1, 100:1, 150:1 
and 200:1) using DA.  
 
3.5.1 Limited proteolysis with DA 
The following ratios of 50:1, 100:1, 150:1 and 200:1 were tested with 2.5 M per subunit TH-
wt before testing with TH-R202H. The protein (TH-wt) was added to buffer and then incubated 
at 25C for 5 min. After 60 s with trypsin the reaction was stopped with TI (1.5 g/ml) and 
analyzed by SDS-PAGE at 300V for 15 min. 20 and 10 µl of the samples were loaded to obtain 
the correct visualization. Different dopamine (DA) concentrations of 5 M, 50 M and 200 M 
with 2.5 M per subunit TH-wt were also tested at 100:1 ratio (TH:trypsin). The proteolysis 
was performed at 25C with pre-incubation of buffer (20 mM Hepes pH 7, 200 mM NaCl) and 
TH for 5 min, Fe2+ for 2 min and DA for 3 min. The reaction was started, stopped and analyzed 
as described. The determined conditions provided from the optimization were applied to the 
final experiment testing the protection of DA and compounds towards proteolysis by trypsin.  
We then performed limited proteolysis by trypsin at a TH:trypsin ratio of 200:1 with 2.5 M 
per subunit of TH (wt and R202H). The proteolysis was performed at 25C where the protein 
was incubated with buffer and 5 M Fe2+ for 2 min before adding 5 M DA for another 3 min. 
The reaction was started by adding trypsin and after 60 s, 1.5 g/ml trypsin soybean inhibitor 
(TI) was added to stop the proteolysis. SDS-PAGE was used to analyze the protection DA 
confers against proteolysis of the N-terminal of TH, at 180V for 45 min. The SDS-PAGE and 
staining of gels were performed as described and subsequently scanned by ChemiDoc XRS + 
from Bio-Rad, and the intensities of the 60 kDa (full-length TH), 57 kDa, 54 kDa bands (section 
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1.3.4) were measured using Image Lab 6.0.1 software. This experiment was performed once 
and thus SD and statistics does not apply. 
3.5.2 Limited proteolysis with hit compounds  
Next, we tested the susceptibility of the protein (2.5 M subunit) to proteolysis by trypsin at 
200:1 ratio (TH:trypsin) with compounds. After some further optimizations, the temperature in 
this assay was 37C. The protein was incubated with buffer and 5 M FAS for 2 min and with 
DA for 3 min afterwards. The reaction lasted for 60 s after adding trypsin and was stopped with 
TI (1.5 g/ml). The bands in lanes with compounds were compared to corresponding band in 
lane without compound by quantification as described in the previous section. The Student`s t-
test was performed (section 3.8) to determine whether the difference was significant compared 
to the control without compound (*p-value <0.05).  
 
3.6 Determination of binding affinities  
Determination of the binding affinity between TH and the compounds was performed using 
Isothermal titration calorimetry (ITC) using the MicroCal ITC-200 instrument (Malvern 
Panalytical). An initial test of 30 µM TH in the cell and 300 µM compound in the syringe was 
carried out at 25C for each of the hit compounds. Powdered compounds were dissolved in 
100% DMSO and diluted in 20 mm Hepes pH 7, 200 mM NaCl until 5% DMSO (300 µM 
compound). TH was diluted in the same buffer supplemented with 5% DMSO. The titration 
was carried out with 1 0.5 µl injection followed by 12 3 µl injections with a stirring speed of 
1000 rpm. Concentrations were adjusted in the next experiments with 90 µM TH instead. The 
data was analyzed by Peter Gimeson (Malvern Panalytical) using PEAQ-ITC software. The 
single set of sites binding model (Wiseman et al., 1989) was applied to obtain affinity constants. 
 
3.7 Molecular docking of hit compounds to TH 
Molecular docking was performed using Schrödinger Release 2018-1: Maestro, Schrödinger, 
LLC, New York, NY, 2018. The hit compounds were docked to the active site of a crystal 
structure of human TH, retrieved from the protein data bank (PDB ID: 2XSN), which contains 
the catalytic domain and tetramerization domain. In addition, the hit compounds were docked 
to the allosteric binding site of the tetrameric TH (PDB ID: 1TOH) by Professor Knut Teigen 
(not described in this section).  
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Firstly, the compounds were prepared by LigPrep for producing low-energy 3D structures from 
2D structures and generating stereochemistry, tautomers and different protonation states. 
Possible protonation states of the ligands were generated in water at pH 7  2 (Schrödinger 
Release 2018-1: LigPrep, Schrödinger, LLC, New York, NY, 2018).  
Secondly, the protein was optimized using the Protein Preparation Wizard which are filling in 
missing partial charges, hydrogens, side chains or whole loop regions, depending on the needs 
of the protein structure (Schrödinger Release 2018-1: Schrödinger Suite 2018-1 Protein 
Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2016; Impact, Schrödinger, 
LLC, New York, NY, 2016; Prime, Schrödinger, LLC, New York, NY, 2018). Water 
molecules were removed from the protein to more extensively explore the binding pocket for 
possible orientations of the docked ligands. Hydrogen atoms were added to optimize the 
hydrogen bonding networks and distances were also minimized. Protonation state of the protein 
was generated at pH 7, taking into account the local environment of each titratable group as 
well as optimization of hydrogen bonding networks.  
The active site iron of TH was defined as center of the pocket to dock molecules into. A receptor 
grid was generated in which the bounding boxes defined the region that the docked molecule(s) 
and the centroid of the docked molecule(s) must occupy to satisfy or pass the initial stages of 
docking.  
Finally, the prepared ligands were docked to the protein using the standard precision (SP) 
protocol ensuring that the ligand sampling were set to be flexible to adapt to the defined active 
site of the protein, with all other options set to default (Schrödinger Release 2018-1: Glide, 
Schrödinger, LLC, New York, NY, 2018). The docking results were analyzed using the Ligand 
Interaction diagram, and the Glide score (gscore) were also used as guidance. BH4 and the 




3.8 Statistical analysis   
As otherwise indicated, experiments were performed in various number of parallels and data 
are represented as the mean and standard deviation (mean ± SD) to quantify the amount of 
variations between the parallels. A p-value was calculated for each compound compared to the 
control in the activity assay (section 3.4.1) and limited proteolysis by trypsin (section 3.5.2). 
For figures with gels, representative results are shown by measuring the intensity of bands as 
described. The p-values were calculated using a two-tailed t-test analysis in Excel, and p < 0.05 




4 Results  
 
4.1 Preparation of pure and stable TH enzymes  
The gene encoding His-MBP-TH was previously cloned into the pET-MBP-1a vector (Bezem 
et al., 2016) and was used as template to make the R202H mutation (Korner et al., 2015). The 
original His-MBP-TH and p.R202H mutant were overexpressed in this work, and a modified 
version of the vector encoding the wild-type fusion protein His-MBP-TH was also attempted 
to be expressed and purified.  
 
4.1.1 Expression and Purification of His-MBP-TH  
The His-MBP-TH proteins were successfully expressed, and fusion proteins of expected size 
were obtained. The purification of the optimized His-MBP-TH by affinity chromatography is 
shown in Figure 4.1A as absorbance at 280 nm versus elution volume. The first very large and 
broad peak in the chromatogram represents the unbound proteins that flows through upon 
washing with Binding buffer. After addition of maltose, the peak representing the fusion protein 
that has bound to the resin appears. An identical chromatogram was obtained for the original 
His-MBP-TH. The mutant His-MBP-TH-R202H was purified by gravity flow without the use 
of a recorder, but the principle is the same. As shown by SDS-PAGE, the elution peak contained 
pure His-MBP-TH for all three fusion proteins (Figure 4.1B). The yield was similar for both wt 
and mutant fusion proteins. 
 
4.1.2 Removal of tag and isolation of TH 
4.1.2.1 Assessing the quality of purified His-MBP-TH proteins by SEC 
After observing the purity of the denatured subunits in SDS-PAGE, the quality of the His-MBP-
TH proteins was evaluated using SEC to ensure that the oligomeric distribution is dominated 
by the functional unit which is a tetramer. As shown in Figure 4.1C-E the main proportion of 
all three fusion proteins elute in the volume corresponding to that of the tetrameric His-MBP-
TH (Bezem et al., 2016). There are negligible amounts of aggregation in all samples, but the 
optimized His-MBP-TH (Figure 4.1D) contains a slight proportion of a band that is believed to 




Figure 4.1: The expression and purification of fusion proteins. (A) Example of chromatographic profile from affinity 
purification of the optimized fusion protein (FP) performed at a flow rate of 2 ml/min showing elution of FP after 
addition of 10 mM maltose at 90 ml. (B) SDS-PAGE of three fusion proteins (FP) in pure form with a precision 
marker (lane 1), optimized FP (lane 2), original FP (lane 3) and His-MBP-TH-R202H (lane 4). Bands at 98 kDa 
correspond to fusion proteins. SEC profiles of purified fusion proteins on a Superdex  200 Increase 10/300 
column performed at a flow rate of 0.5 ml/min are shown for the original His-MBP-TH (C), the optimized His-MBP-
TH (D) and the His-MBP-TH-R202H mutant (E). Peak 1 represents aggregated and/or octameric proteins and peak 
2 is the tetrameric fusion protein. 
 
4.1.2.2 Cutting tests with TEV-protease 
To examine the efficiency of TEV-protease to separate TH from the fusion partner, cutting tests 
were performed on the purified fusion proteins and the result was analyzed by SDS-PAGE. As 
shown in Figure 4.2A, increasing the incubation time to 3 hours or decreasing the TEV:MBP-
TH ratio to 1:10 did not have any effect on the cutting efficiency for the optimized His-MBP-
TH. As a control we compared the cutting of the optimized His-MBP-TH to the original fusion 
protein (Figure 4.2B) and TEV-protease cuts the original protein as expected (complete cutting 
at 1:10 TEV:MBP-TH ratio at 3 hours). In an attempt to facilitate access to the cleavage site, 
we added 0.5 M urea (Hung et al., 2014). However, this had no effect on cutting of the optimized 
His-MBP-TH (Figure 4.2B). The original His-MBP-TH was cut equally well with and without 
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urea (Figure 4.2B). The TEV cutting test, performed at three different ratios, showed that 1/10 




Figure 4.2: SDS-PAGE of cutting tests. (A) Optimized His-MBP-TH tested at 1:50 and 1:10 ratio (TEV:TH) after 1, 2 
and 3 hours, respectively. (B) Original (left) and optimized His-MBP-TH (right) with addition of urea at ratios of 
1:10 and 1:5 (TEV:TH). (C) Isolated fusion protein (FP) of His-MBP-R202H-mutant cut in ratios of 1:100, 1:50 and 
1:10. The gel lacks the LMW marker but corresponds in size as in (A) and (B). Bands at 98, 60, 43 and 27 kDa 
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4.1.2.3 Isolation of TH  
As the optimized His-MBP-TH is not cut with TEV protease under standard or additionally 
tested conditions, this novel construct was abandoned, and all the following work was 
performed using the original His-MBP-TH and the His-MBP-TH-R202H mutant. Both fusion 
proteins were successfully cut with TEV-protease and analyzed by SEC. The elution profiles 
for separation of fusion partner and aggregates from the TH proteins are shown in Figure 4.3A 
and C for TH-wt and TH-R202H, respectively. Fractions containing tetrameric TH were pooled 
and concentrated. The yield of TH-wt was 34% of the fusion protein and the yield of TH-R202H 
was 24%. Both TH proteins were obtained in a pure form (4th lanes in Figure 4.3B and D).  
 
 
Figure 4.3: Removal of fusion partner. (A) Separation of TH-wt (peak #2) and fusion partner His-MBP (peak #3) 
on a Superdex  200 Increase 10/300 column. (B) SDS-PAGE profile of TH-wt representing fusion protein (lane 2), 
TEV cutting with TEV:MBP-TH ratio at 1:10 (lane 3) and 1 µg isolated TH-wt (lane 4) (C) Separation of TH-R202H 
(peak 2) and His-MBP (peak 3) on a Superdex  200 Increase 10/300 column. Peak 1 elutes at the position 
corresponding to aggregated proteins. (D) SDS-PAGE profile of TH-R202H. Lanes 1-4 correspond to the SDS-PAGE 




4.1.3 Finding an appropriate buffer for TH by DSF 
4.1.3.1 RUBIC Buffer Screen  
To test for optimal buffer conditions for TH, we tested the commercial RUBIC Buffer Screen 
MD1-96 with 96 different buffer conditions using DSF. Following the protocol for this screen, 
the Tm of the assayed protein in pure water is defined as Tm,ref, and for TH this was 50.9C 
(shown in blue in Figure 4.4A). Buffers that provided 2-5C thermal stability of TH, compared 
to Tm,ref, were in the range of 0.03 – 0.15 M Tris-HCl at pH 7.5-8.0 with addition of 0.15 M 
NaCl (see Appendix). As shown in Figure 4.4B, the highest stabilization was obtained in 0.12 
M Tris-HCl and 0.15 M Tris-HCl, indicating that Tris-HCl is the preferred buffer type for 
enhanced TH thermal stability within pH 7-8. However, as the pH of Tris-buffers are affected 
by temperature they are not optimal for these experiments. We thus decided to continue using 
the purification buffer from SEC (20 mM Hepes pH 7, 200 mM NaCl) and rather optimize this 
buffer for future compound screening. 
 
  
Figure 4.4: Effect of buffer conditions on TH thermal stability showing fraction of unfolded protein (Fu) on 
increasing temperature for TH in pure water (blue) and the other 95 buffer conditions (grey) (A). Stabilizing buffer 
conditions (B) are obtained at 0.03 M (red), 0.06 M (cyan), 0.12 M (blue), 0.15 M (pink) Tris-HCl and at 0.15 M 
NaCl with 0.06 M Tris-HCl (yellow) compared to Tm,ref. Lower panels show the first derivative and vertical lines 
denote the Tm.. The fluorescence signal is scaled to 0-1. 
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4.1.3.2 NaCl concentrations  
The stability of TH was further tested in 20 mM Hepes pH 7 at different NaCl concentrations 
as described in section 3.2.4.2. Although the highest stabilization was obtained with 20 mM 
Hepes pH 7 and 400 mM NaCl, which represents a high ionic strength, we decided to continue 
using 200 mM NaCl for screening purposes. The 400 mM NaCl buffer can be used in future 
experiments where a higher stability of TH is needed, e.g. for crystallization. 
 
4.2 Finding potential pharmacological chaperones for TH  
In this work, we have used TH-wt to screen for compounds and validate them further. However, 
we have also purified the TH-R202H mutant that might be a target for the future chaperone 
therapy. Some experiments have therefore been performed also on this TH enzyme and the 
preliminary results from these are shown in section 4.7. 
 
4.2.1 Screening of the NOCE library 
The graphs in Figure 4.5A represent the screening of TH in presence of each of the 344 
compounds in the NOCE library. The melting curves of TH in presence of compounds at a final 
concentration of ~100 µM and 5% DMSO are shown in grey and the control (TH without 
compound, but with 5% DMSO) is shown in blue. The Tm obtained for the DMSO control, i.e. 
Tm,ref, was 50  0.4C. Seven hits from the NOCE library were selected for further examination 
as they provided stabilization of TH of  1.8C (Figure 4.5B). The 19 hits from the FDA library, 
identified previously by Dr Magnus Hole, were also included for further concentration-
dependent binding analysis. Thus, the HTS of the FDA and NOCE libraries has led to 




Figure 4.5: Screening of NOCE library. (A) The melting curves of TH represented as fraction of unfolded protein 
(Fu) upon increasing temperature. TH without compound is shown in blue and in the presence of each of the 344 
compounds in grey. (B) Compounds stabilizing TH  1.8C were selected as primary hits. The lower panels show 
the first derivative and vertical lines denote the Tm. The fluorescence signal is scaled to 0-1.  
 
4.2.2 Validation of primary hits 
4.2.2.1 First validation  
To exclude false positives among the 26 primary hits, a concentration-dependent binding assay 
was performed in two stages. In the first validation, we obtained 8 hit compounds that provided 
stabilization of TH. The hit compounds selected showed that the effect decreased with lower 
compound concentration as shown in Figure 4.6, and this indicates that the compounds are 
indeed binding and stabilizing the enzyme. These compounds are named 1-8 and the remaining 





Figure 4.6: The concentration-dependent effect of compounds 1-8 on the Tm of TH. The four-parameter logistic 
nonlinear regression equation in SigmaPlot was used for curve fittings. 
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4.2.2.2 Second validation  
The second validation was performed as the first, but with more concentrations. The compounds 
that give a sigmoidal shape when plotting the Tm of TH versus compound concentration are 
shown in Figure 4.7. Compound 1, 3, 6 and 8 did not show a good binding curve with the 
increasing number of concentrations and were therefore excluded. However, compound 8 is 
identified as DA which is known as a natural feedback inhibitor of TH. DA has a stabilizing 
effect on TH only at low concentrations and it does not display a concentration-dependent curve 
in the concentration range that we are using (not shown). 
The four-parameter logistic nonlinear regression equation was used for curve fitting in 
SigmaPlot to obtain EC50. From the fittings shown in Figure 4.7 the EC50-values obtained 
showed the following order with respect to apparent binding affinity: compound 4 >  compound 
2 > compound 5 > compound 7. Values are shown in Table 4-1.  
 
 
Figure 4.7: The concentration-dependent stabilization of compounds 2, 4, 5 and 7 on TH. To determine EC50 values, 
the points were fitted using four-parameter logistic nonlinear regression equation in SigmaPlot. 
 45
 
Thus, the hit compounds with pharmacological chaperone potential for TH are considered as 
follows: Trimethoprim (compound 2), N6-methyladenosine (compound 4), Azacytidine-5 
(compound 5) and Levalbuterol-HCl (compound 7). We also decided to include DA in further 
studies (Table 4-1). 
 
Table 4-1: The compound name, 2D-structure and kinetic parameters are shown for the selected hit compounds.  



















1.9 5.3  0.6 - 
5 Azacytidine-5 
 
1.3 8.6  1.5 - 
7 Levalbuterol-HCl 
 
1.7 9.2  1.1 3.38  
2.52x10-7 
8 Dopamine HCl 
 



























4.3 Evaluating the effect of hit compounds on TH activity  
4.3.1 Testing inhibitory effect on TH  
To exclude hit compounds with inhibitory effect on TH activity, an enzymatic activity assay in 
presence of each hit compound at 100 µM was performed. The results showed that 
Levalbuterol-HCl and Azacytidine-5 had no effect on TH-activity while Trimethoprim 
increased the activity by ~20% (Figure 4.8A). N6-methyladenosine causes a ~12% decrease in 
TH activity, but the DA, identified as a hit in the HTS and a known feedback inhibitor of TH, 
almost abolishes TH activity (~97% reduction at 100 µM) (Figure 4.8A). The inhibitory 
potential of both inhibitors was analyzed by performing the activity assay at a range of 
compound concentrations, which also provides the IC50, and by this method the inhibitory effect 
of N6-methyladenosine was actually determined to be very low. For DA, the IC50 was 
determined to be 1 µM (Figure 4.8B).  
 
Figure 4.8: (A) The effect of the hit compounds on the activity of TH. The red line marks the activity in absence of 
compound. The full compound names are N6-methyladenosine (N6), Levalbuterol-HCl (Leval), Trimethoprim 
(Trim), Azacytidine-5 (Aza), and dopamine (DA). (B) IC50 curve for DA showing strong inhibition of TH at high 
concentrations. Determination of IC50 value of DA was done using the four-parameter logistic nonlinear regression 
equation in SigmaPlot. * p<0.05 compared with the control without compound, as calculated by t-test analysis is 




4.4 Protection of TH towards limited proteolysis by trypsin 
We performed the proteolysis according to Hole et al. and also obtained fragments migrating 
in the SDS-PAGE gel according to molecular weights of 60 kDa (full-length), 57 kDa and 
52-54 kDa (Hole et al., 2015). The rate of this cleavage of TH is decreased through binding and 
stabilization by DA (see section 4.7 about the R202H mutant) and the ability of the hit 
compounds to also confer protection is a good test to include in the process of finding a 
pharmacological chaperone.  
 
4.4.1 Limited proteolysis with hit compounds 
After optimizing the experiment according to different TH:trypsin ratio and reaction time (not 
shown), conditions of 200:1 (TH:trypsin) and 60 s were applied to the final test and the results 
are shown in Figure 4.9. The results from the effect of proteolysis of TH by the four compounds 
are presented as means of three parallels and given as percentages of the control (no trypsin), 
which was set to 100% (Figure 4.9A).  
Contrary to the protection towards TH proteolysis shown by DA (Hole et al., 2015), TH is 
proteolyzed to the same extent both without and with the four hit compounds. In fact, for all 
the compounds except Levalbuterol-HCl, the proteolysis of the N-terminal was rather slightly 






Figure 4.9: The effect of compounds on limited proteolysis of TH. (A) Values from triplicate measurements show 
percent remaining full-length TH (60 kDa band) (black) and emergence of the characteristic bands at 57 (light 
grey) and 54 kDa (dark grey). (B) The SDS-gel shown is from one of three measurements. Lane 1: Precision marker; 
lane 2: uncut full-length protein; lane 3: N6-methyladenosine(N6); lane 4: Levalbuterol-HCl (Leval); lane 5: 
Trimethoprim (Trim); lane 6: Azacytidine-5 (Aza). *p<0.05 compared with the control with trypsin without 
compound, as calculated by t-test analysis. 
 
 
4.5 Determination of binding affinities 
4.5.1 Determination of Kd by ITC 
The first set of ITC experiments were performed to determine the Kd-value for the binding of 
the compounds to TH, which is a more adequate measure of affinity than the EC50 obtained 
from concentration dependent DSF (see above). At 30 µM protein and 300 µM compound, the 
raw data plots indicated binding for only two of the four hits; Trimethoprim and 
Levalbuterol-HCl (Figure 4.10). The thermogram for Levalbuterol-HCl (Figure 4.10D) shows 
that the first peak represents a very high heat pulse while it already at the second injection is 
much smaller. This indicates that the protein has reached the point of saturation too rapidly for 
analysis. While the raw thermogram for Trimethoprim could be analyzed at this concentration 
(Figure 4.11A), the titration was carried out a second time with increased protein concentration 
(90 µM) for Levalbuterol-HCl to provide more available proteins for ligands to bind (Figure 






Figure 4.10: Raw data from ITC binding experiment. Titration of 30 µM TH with 300 µM (A) N6-methyladenosine, 
(B) Azacytidine-5, (C) Trimethoprim or (D) Levalbuterol-HCl at 25C.  
 
 
The data were kindly analyzed by Peter Gimeson (Malvern Panalyticals) using the Malvern 
PEAQ software. The area under the heat pulses shown as peaks in the thermograms for both 
Trimethoprim and Levalbuterol-HCl were integrated and a single set of sites model was applied 
as shown in Figure 4.11. This gives Kd-values of 0.51  1.76x10-7 M and 3.38  2.52x10-7 µM 
for Trimethoprim and Levalbuterol-HCl, respectively. These values are much lower than the 
EC50 values obtained with concentration-dependent DSF (Table 4-1), but both parameters show 
that Trimethoprim displays highest affinity for TH. Applying the model also gives a value for 
the reaction stoichiometry (n) and therefore the number of binding sites per TH subunit. The 
values obtained were 0.24  3.7x10-4 for Trimethoprim and 0.45  1.5x10-2 for 
Levalbuterol-HCl. These values are very low, but this could be due to overestimation of the 
concentration of actively binding TH. If e.g. iron is needed for the binding, only the TH subunits 
with iron in the correct state can bind. Furthermore, another explanation for n  per TH 
subunit would be a binding of the compounds to intersubunit regions, with 1 compound per 





Figure 4.11: The binding of Trimethoprim and Levalbuterol-HCl to TH studied by ITC. (A) 30 M TH was titrated 
with 300 µM Trimethoprim and (B) 90 M TH was titrated with 300 M of Levalbuterol-HCl. The upper panels 
show the thermograms for binding of the compounds to TH. The lower panels show the binding curve where each 
point represents the integrated heat pulses of each corresponding peak in the thermogram fitted to a single-set-
of-sites  
 
4.6 Molecular docking  
Lastly, molecular docking was performed for all four hit compounds. Figure 4.12 shows the 
binding of the compounds into the active site of the catalytic domain of TH. We see that two of 
five compounds (2 and 7) appear to bind in the substrate-analogue (thienylalanine) binding 
pocket (Figure 4.12B, E), suggesting a possible binding mechanism of competition between the 
compound and substrate. Thienylalanine (THA) is used for visualization as it is thought to bind 
and occupy TH in a similar manner as PAH (Teigen et al., 2007). Docking of compounds to 
TH predicts the binding affinity by utilizing the scoring function, gscore, as shown in Table 
4-2. As expected, DA obtained the highest negative gscore, indicating a strong binding. N6-
methyladenosine seems to mainly occupy the cofactor binding site which might explain the 
observed effect it has on TH-activity. Overall, the gscore predicts that the strongest and weakest 




The program Fpocket (http://fpocket.sourceforge.net/) identified an intradimeric - possibly 
allosteric - site in TH (Figure 4.13). Docking to this binding site, at the interphase between the 
monomers in both TH dimers (2 binding sites per tetramer), was also performed as seen in 
Figure 4.13 (Le Guilloux et al., 2009). Contrary to the gscore obtained for the hit compounds 
when docking to the active site, except for Trimethoprim, the obtained gscores when docking 
to the allosteric binding site of TH are more negative, i.e. indicating higher affinity. The gscore 




Figure 4.12: Molecular docking models. Binding of compounds in the active site of TH, here shown with the iron 
as a grey sphere (left). Compounds (green sticks) shown together with BH4 and thienylalanine (THA). Both cofactor 
and THA are displayed in grey. The complexes composed of TH (PDB ID: 2XSN) and compounds are shown in 2D 
representations showing interactions between the ligand and residues within the active site (right). Purple 
denotes H-bonding, red denotes Pi-cation interactions, green denotes Pi-Pi stacking and blue/pink indicates salt 




Figure 4.13: Docking of hit compounds to the putative allosteric site identified by Fpocket (colored in orange) at 
the interphase between the monomers of the tetrameric structure of TH (shown in green). Each compound is 
shown individually in the allosteric binding site (A) Trimethoprim, (B) N6-methyladenosine, (C) Azacytidine-5 and 
(D) Levalbuterol-HCl.   
 
Table 4-2: Hit compounds from molecular docking represented with compound numbers, name, 2D structure 
and Glide score (gscore).  
 1Docking to the active site 
2 Docking to the allosteric binding site  






2 Trimethoprim - 5.2 - 5.1 182.8 
4 N6-methyladenosine - 4.9 - 5.9 50.3 
5 Azacytidine-5 - 5.5 - 6.2 29.1 
7 Levalbuterol-HCl - 5.3 - 6.2 27.3 
8 Dopamine-HCl - 6.4 - 6.8 10.6 
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4.7 The mutant TH-R202H 
This THD-associated mutant has been studied earlier showing that the TH-R202H has reduced 
stability (Calvo et al., 2010) and is not stabilized by DA-binding (Korner et al., 2015). It is 
common to purify low amounts of unstable proteins, but the purification process proceeded in 
this work shows otherwise. Before studying the effect of the hit compounds identified using 
TH-wt, we performed some experiments to verify that our purified TH-R202H is behaving as 
previously described (Calvo et al., 2010; Korner et al., 2015).  
4.7.1 Testing the effect of DA on TH-R202H mutant  
4.7.1.1 Stabilizing effect of DA on TH-R202H  
By using DSF, we can see that the TH-R202H mutant purified in this work displays higher Tm-
values than previously reported (Calvo et al., 2010; Korner et al., 2015), i.e. 50.9 ± 0.17°C. 
This is almost as stable as TH-wt at 51.5 ± 0.36°C (Grey lines in Figure 4.14A and B). However, 
the results clearly show that DA stabilizes the mutant much less than the increase of 3-4°C for 
TH-wt (Figure 4.14A and B and Figure 4.15). Thus, as earlier reported by Korner et al., the 
mutant is indeed much less stabilized by DA than TH-wt (Korner et al., 2015). As seen in Figure 
4.15 the stability of TH (both wt and R202H) decreases with increasing concentration of DA.  
Interestingly, the first derivative graphs of TH-wt – where the Tm values are easily observed – 
show one peak in the absence of DA and two peaks in the presence of DA (Figure 4.14A). Two 
unfolding peaks have shown to be characteristic for PAH as the RD melts before the CD upon 
increasing temperature (Thorolfsson et al., 2002). Moreover, the TH-R202H mutant shows 
three, or at least two, unfolding peaks even in the absence of DA (Figure 4.14B), suggesting 
that the mutation somehow changes the structure possibly making the OD, RD and CD of the 
mutant unfold under different temperatures. The different peaks are less prominent in the 




Figure 4.14: Stabilization by stoichiometric amounts of DA. The melting curves are represented as fraction of 
unfolded protein (Fu) upon increasing temperature. (A) TH-wt without DA (Tm 51.5 ± 0.36°C, grey lines) and with 
1X DA (55.3 ± 0.3°C, colored lines) and (B) TH-R202H without DA (Tm 50.9 ± 0.17°C, grey lines) and with 1X DA 
(52.4 ± 0.09°C, colored lines). The lower panels show the first derivative and vertical lines denote the Tm. In both 
panels the fluorescence signal is scaled to 0-1.  
 
Figure 4.15: The effect of DA on TH stability. The Tm values of unfolding for TH-wt (black circles) and TH-R202H 




4.7.1.2 Protective effect of DA on TH-wt and TH-R202H mutant  
Limited proteolysis was performed with DA on TH-R202H using TH-wt as a control and the 
results are shown in Figure 4.16. The density of each band on the gel was measured and 
displayed as a bar plot. The results obtained show that the TH-R202H mutant is in fact less 
prone to trypsinization than TH-wt, but it is proteolyzed to the same extent both without and 
with DA. The protection of TH-wt proteolysis by DA is in agreement with results from earlier 
studies (Hole et al., 2015; McCulloch & Fitzpatrick, 1999), likewise for the less protection by 
DA for the TH-R202H mutant (Korner et al., 2015). 
 
 
Figure 4.16: Trypsinization of (A) TH-wt and (B) TH-R202H, and effect of DA. The figures show the measured band 
intensities from the SDS-PAGE gels (representative gels shown in the insets). In the gels, lane 1: Precision marker; 
lane 2: uncut full-length protein; lane 3: with trypsin; lane 4: with trypsin and DA. The experiment was performed 




4.7.2 Testing effect of hit compounds on R202H mutant 
4.7.2.1 Determination of EC50 with hit compounds using DSF 
Figure 4.17 shows the effect of hit compounds on the mutant. Here, Trimethoprim shows no 
effect on the thermal stability on TH-R202H although it stabilizes TH-wt. Among the primary 
hits, N6-methyladenosine shows less effect on the stability of the mutant, compared with TH-
wt. Both Levalbuterol-HCl and Azacytidine-5 cause a dose-dependent stabilization of the 
R202H-mutant, but to a lesser extent than TH-wt.  
 
 
Figure 4.17: Concentration-dependent curves showing the effect of compounds 2, 4, 5 and 7 on TH-R202H. The 
change in temperature is plotted against compound concentration representing the mean SD. The data were 




4.7.2.2 Limited proteolysis with hit compounds  
Figure 4.18 shows the results from protection from proteolysis of TH-R202H by the four hit 
compounds which are presented as means of three parallels in the bar plot (Figure 4.18A) and 
given as percentages of the control (TH-R202H without trypsin, set to 100%). A representative 
gel is shown in Figure 4.18B. Similar to what has been shown for TH-wt, the hit compounds 
did not protect TH-R202H from limited proteolysis by trypsin, except for Levalbuterol-
HCl which shows a significant protection (p-value <0.1). In fact, the other 
compounds appear to slightly accelerate trypsinization on the N-terminal, however without 




Figure 4.18: The effect of compounds on the limited proteolysis of TH-R202H. (A) Values from triplicate 
measurements show percent remaining of full-length TH (60 kDa band) (black) and the truncated forms at 57 kDa 
(light grey) and 54 kDa (dark grey). (B) The SDS-gel shown, are from one of three measurements. Lane 1: Precision 
marker; lane 2: uncut full-length protein; lane 3: N6-methyladenosine(N6); lane 4: Levalbuterol-HCl (Leval); lane 
5: Trimethoprim (Trim); lane 6: Azacytidine-5 (Aza).    
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5 Discussion  
The lack of an effective treatment of THD, especially for the most severe form (Type B), has 
prompted the investigation on pharmacological chaperones as an alternative therapy for this 
disorder. Although L-DOPA has shown to improve the symptoms of THD, there are side effects 
and insufficient response associated with L-DOPA treatment. In this work, we have focused on 
finding compounds with pharmacological chaperone potential for TH including the most 
common misfolding mutation in THD, the TH-R202H mutant. Here follows a discussion of the 
results obtained.  
Effort to make an optimized TH did not succeed 
Just prior to this masters project, an attempt to create an improved version of the published His-
MBP-TH fusion protein (Bezem et al., 2016) was made with the aim to remove some extra 
amino acids at the N-terminus by site-directed-mutagenesis. The extra amino acids are removed 
as they are remnants after expression of recombinant fusion proteins. This required the amino 
acid sequence around the TEV-protease cleavage site (ENLYFQ/G) to be reduced by 3 amino 
acids (GAM), and thus the linker between the MBP and TH became shorter (Figure 3.1). The 
expression and purification of the published and optimized His-MBP-TH is identical, but this 
change has surprisingly shown to influence the access to the TEV protease cutting site between 
His-MBP and TH so much that the cutting is completely abolished for this optimized His-MBP-
TH. Although recombinant fusion proteins offer many advantages, this result clearly shows that 
there are also drawbacks. In this specific case 3 extra amino acids at the N-terminus could not 
be avoided. Luckily, for this project, where this region is not the focus of the study, these 
residues are not expected to influence the results, but for other experiments having a native N-
terminus can be important. 
Five primary hit compounds identified on TH  
The screening and concentration-dependent binding assay identified compounds that increased 
the thermal stability of TH. In this DSF-based high throughput method used to determine 
conditions and identify compounds that affect the protein stability one must accept the 
drawback of potentially missing out some compounds that might have a stabilizing effect on 
the enzyme. Some reasons are that parallel samples are not customarily performed, the 
solubility of each compound in the chosen buffer is not tested and because one cannot check 
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each melting curve for artefacts. However, this is a known drawback of HTS that is accepted 
because an efficient method is indeed needed when screening large compound libraries. Starting 
out with 1624 compounds in the screening of the FDA-approved and NOCE libraries, resulted 
in five validated hit compounds Trimethoprim, N6-methyladenosine, Azacytidine-5 and 
Levalbuterol-HCl. In addition to these potential pharmacological chaperones, dopamine-HCl, 
which is present in the FDA library, was identified as a hit in the initial screening. Identifying 
DA, the natural feedback inhibitor of TH, as a binder in the screening was reassuring and since 
the TH-DA interaction is well characterized we decided to include it as a negative control in 
the following steps. 
The hit compounds most probably bind outside the active site 
In the validation steps using DSF, the four hit compounds displayed a characteristic sigmoidal 
curve with EC50-values between 4 and 10 µM. These values were obtained by using Logistic 
nonlinear regression four-parameter function in SigmaPlot. The EC50-value can be viewed as 
an approximation of the Kd value, but with an absolute requirement of very good data. Our 
experiments unfortunately had high experimental errors especially at low compound 
concentrations and thus we employed ITC, a method that can determine the accurate Kd-value 
for binding and does not require a dye. The thermograms for both N6-methyladenosine and 
Azacytidine-5 did not show any binding to TH probably due to the chosen protein and 
compound concentration for these initial experiments. The chosen protein concentration in this 
experiment (30 µM) is an appropriate start concentration when the Kd is unknown, but more 
ITC-experiments at higher protein concentrations must be performed to properly measure the 
Kd for these two hits.  
The thermograms for Trimethoprim and Levalbuterol-HCl showed binding to TH with good 
concentration dependent data to provide a Kd value of 0.51  1.76x10-7 M and 3.38  2.52x10-
7, respectively. These values are much lower than the approximate Kd-values obtained with 
concentration-dependent DSF, and the low value indicates a strong binding affinity towards the 
protein. Based on these results, Levalbuterol-HCl and Trimethoprim are the only compounds 
that might have a stabilizing effect for TH. Applying the single set of sites-model also gave a 
value for the reaction stoichiometry (n) and therefore the number of binding sites per TH 
subunit, which were 0.24  3.7x10-4 for Trimethoprim and 0.45  1.5x10-2 for Levalbuterol-
HCl. For compounds binding to the active site of TH, the n-value is expected to be 1, and a low 
n-value suggests that not all TH is binding the compound or, more probably, that the compounds 
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bind at intermonomer sites (e.g. n=1 per dimer). The docking results showed that all four hit 
compounds should be able to bind in the active site, although with less affinity than DA (gscore 
of -6.4 kcal/mol) that is well known to bind directly to the active site iron (Andersson et al., 
1988). However, they also dock to the interphase between the monomers in each of the dimers 
in the tetrameric structure of TH. In fact, to this allosteric binding pocket they appear to bind 
better (a more negative gscore) than to the active site.  
Since the n-values of both compounds are closer to 0.5, this supports the latter docking result, 
which would explain n=1 per TH dimer (2 per tetrameric unit). Another result supporting that 
the compounds bind outside the active site is from the TH activity assay in presence of the hit 
compounds. The results showed that none of the four hit compounds affected the enzyme 
activity in an inhibitory manner and thus are unlikely to compete with the natural ligands for 
binding to the active site. The feedback inhibitor DA was included in the assay and almost 
abolished TH activity as expected (~97% reduction). Indeed, when the hit compounds and DA 
were docked to the active site of TH, a better gscore was obtained for DA than the four hit 
compounds. Thus, all the results obtained so far are supporting that the compounds bind in other 
binding pockets than the active site. 
 
The binding of FDA-approved hit compounds on TH might explain their side effects 
The four hit compounds that have shown to bind and stabilize TH in this work are identified 
from the off- patent FDA-approved drug library, where 95% drugs have been licensed by the 
US Food and Drug Administration for medical use. To date, the drugs are used to treat different 
disorders and conditions. Trimethoprim is an antibiotic used for treatment of infections, 
especially urinary tract infections but also used in combination with other drugs to treat 
pneumonia and diarrhea. Levalbuterol-HCl, also known under the market name Xopenex, is 
a short-acting beta agonist (SABA) used in asthma treatment and chronic obstructive 
pulmonary disease (COPD). Azacytidine-5 (Vidaza) is an antineoplastic drug used in cancer 
treatment and has been licensed for use in all subtypes of myelodysplastic syndromes (MDS) 
and/or myeloid leukemia after intensive chemotherapy (Raj et al., 2006). To our knowledge 
there is no reports on N6-methyladenosine as a drug. N6-methyladenosine is a modified mRNA 
where the adenosine base at the nitrogen 6-position is methylated and this modification of the 
human mRNA molecules has been shown to play a critical role in various cancer development 
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(Niu et al., 2018). It will be interesting to see if TH-related side effects are seen when and if the 
molecule comes into the market as a potential drug.  
Interestingly, common side effects using Trimethoprim are nausea, vomiting, diarrhea, itching 
and rash. Vomiting and nausea are often connected to stimulation of the dopamine D2-receptor 
which is located in the chemoreceptor trigger zone (CTZ) in the brain. The stimulation of the 
D2-receptor causing these side effects can potentially be explained by the strong binding affinity 
(a low Kd) and the increasing effect that Trimethoprim had on TH activity leading to higher 
levels of DA. In fact, it has been addressed elsewhere that Trimethoprim affect the 
catecholamine synthesis pathway, resulting with an increased level of neurotransmitters (Sakai 
et al., 1995). The study suggests that Trimethoprim, an inhibitor of dihydrofolate reductase 
(DHFR), also act on the CNS enzyme dihydropteridine reductase (DHPR) in the recycling 
synthesis of BH4. Inhibition of both enzymes is thought to decrease the regeneration of BH4, 
which in turn should result in a feedback stimulation to the synthesis of BH4 from guanosine 
triphosphate (GTP). This indeed suggest that Trimethoprim might have several acting 
mechanisms within the catecholamine synthesis pathway leading to an increase level of 
neurotransmitters.  
Moreover, one of many common side effects reported for Levalbuterol-HCl is shaking. Despite 
the fact that the activity measurements did not proof inhibition, it seems that this compound 
might alter DA synthesis leading to a reduced amount of DA which is associated with shaking 
and tremor, a Parkinson-like side effect. Insomnia has also been reported as a side effect and it 
is well known that the sleep onset is associated with changes in levels of circulating 
catecholamines (Irwin et al., 1999). Additionally, the inhibition of the biosynthesis of 
catecholamines has been shown to induce a temporary hypersomnia increasing both paradoxical 
sleep and slow wave sleep. Other side effects mentioned in the product info of the drug includes 
anxiety, nervousness, dizziness and nausea. In fact, this is supported by a study showing that 
treatment with a TH-inhibitor, alpha-methyl-p-tyrosine (AMPT), has shown to cause similar 
side effects such as pathological anxiety, decreased calmness, increased depression, sleepiness, 
tension and anger (McCann et al., 1995).  
Chemotherapy-induced nausea and vomiting is a common side effect of many cancer treatment 
and this side effect is mentioned in the product info of Azacytidine-5 (Vidaza) among other 
side effects such as tiredness, insomnia, anxiety and dizziness. The adverse reaction is often 
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associated with levels of neurotransmitters, which can possibly explain the side effects using 
Azacytidine-5 as discussed above for Levalbuterol-HCl.  
 
The TH-R202H mutant is stable, but is not properly regulated by DA 
There are studies that have been conducted on the THD-associated mutant showing that the 
TH-R202H has reduced stability (Calvo et al., 2010) and is not able to bind DA (Korner et al., 
2015). In this work, our purified mutant has shown to behave differently. The purification 
yielded a good amount of TH-R202H, which is unexpected if the protein is unstable. When 
removing the fusion partner from TH-R202H, the protein still remained stable to an extent 
reflected by the percentage yield of 24% compared to the wild-type of 34%. This is supported 
by the results obtained from the DSF-based HTS showing that the mutant displays a much 
higher Tm-value than previously reported (Calvo et al., 2010), i.e. 50.9 ± 0.17°C which is very 
close to the stability of TH-wt at 51.5 ± 0.36°C.  
In agreement with earlier results reported by Korner et al. (Korner et al., 2015), the TH-R202H 
mutant is stable, but is not properly regulated by DA. The results clearly show that DA stabilizes 
the mutant much less than TH-wt (1-2°C vs. 3-4°C) indicating that the mutant does bind to DA 
but is not able to be stabilized to the same extent as TH-wt. This is in fact also supported by the 
results obtained for limited proteolysis by trypsin showing that DA does not protect TH-R202H 
against trypsinization. This suggest further that the mutation of arginine (R) to a histidine (H) 
in position 202 somehow changes the tetrameric structure and that the mutant has 
conformational defects that appears to change the interactions between domains. This is 
supported by the DSF profiles with more disengaged domain transitions in forms of different 
unfolding peaks. Other mutations decrease more the stability and increase the mobility, 
therefore increasing the proteolysis, but for the TH-R202H mutant it seems that we have a 
discrete conformational change. This explains the different concentration-dependent binding 
profiles obtained for TH-wt and TH-R202H with each hit compound. E.g. Trimethoprim 
showed no effect on the thermal stability of TH-R202H, contrary to TH-wt.  
 
One of four hit compounds can be considered a possible candidate for pharmacological 
chaperone therapy for TH 
In the beginning of this work, four compounds were identified as hits based on the 
concentration-dependent binding DSF profiles. So far, only one of these four hit compounds 
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show potential as a pharmacological chaperone. As mentioned earlier, Trimethoprim did not 
exert any effect on the thermal stability on TH-R202H. There are large standard deviations at 
lower concentration of N6-methyladenosine as seen in the DSF-profile and the protective effect 
of Azacytidine-5 towards proteolysis of the mutant is not significant. Although the inhibition 
of Levalbuterol-HCl in the activity assay is non-significant compared to the other compounds, 
it binds with high affinity (the low Kd-value obtained by ITC) and still show an effect on the 
thermal stability of TH. This is supported by the large negative gscore obtained by molecular 
docking at the allosteric binding pocket as the compound most probably bind outside the active 
site as discussed earlier. In fact, Levalbuterol-HCl is the only compound that shows significant 
(p<0.05) protection towards proteolysis of the 57 kDa truncated form of TH-wt and a trend is 
also seen (p<0.1) for the mutant. Altogether, the data from this work identifies 
Levalbuterol-HCl as a potential pharmacological chaperone that may increase the steady state 
levels of TH in cells and in vivo. 
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6 Conclusion  
The main aim with this work was to find potential pharmacological chaperones that stabilize 
tyrosine hydroxylase (TH) and its disease-associated mutant, TH1-p.R202H. From the 
experimental screening and validation, we discovered four primary hit compounds. All four hit 
compounds point towards binding of allosteric binding pockets of TH rather than the active site 
and only one compound could be identified as a potential pharmacological chaperone. This 
work has also provided important information regarding side-effects of these FDA-approved 
drugs possibly caused by their ability to bind and stabilize TH. We have gained a better insight 
into the THD-associated mutant R202H, which so far appears to confer a discrete 
conformational change affecting the proper stabilization by DA, but the stability of the protein 




7 Future work  
To obtain more knowledge about the four hit compounds as potential pharmacological 
chaperones, future work should include further validation assays to gain a deeper understanding 
of the stabilizing effect of the compounds on both TH and TH-R202H. This is essential for the 
compounds to be applied as potential drug candidates for THD treatment.  
For one of the compounds the stabilizing effect shown in the DSF-profile on the TH-R202H 
mutant is not strictly significant, due to the large standard deviations obtained. The experiment 
should be repeated in order to validate our findings. Moreover, two of four hit compounds did 
not show any form for binding to TH using ITC, probably because of the chosen protein- and 
compound concentration. Thus, more ITC-experiments at higher protein concentrations must 
be performed to properly measure the Kd for these two hits. Their effects on the TH should also 
be tested and analyzed to explore their functionality and toxicology in cells and eventually in 
animal models. To be able to fully understand the binding of the compounds on the enzyme, 
the full-length crystal structure of TH should also be solved. This enable further docking 
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